Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

@article{Block2017EffectOT,
  title={Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.},
  author={Geoffrey A. Block and David P Rosenbaum and Maria Leonsson-Zachrisson and Magnus {\AA}strand and Susanne Johansson and Mikael Knutsson and Anna Maria Langkilde and Glenn M. Chertow},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2017},
  volume={28 6},
  pages={
          1933-1942
        }
}
Hyperphosphatemia is common among patients with CKD stage 5D and is associated with morbidity and mortality. Current guidelines recommend lowering serum phosphate concentrations toward normal. Tenapanor is a minimally absorbed small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 that functions in the gut to reduce sodium and phosphate absorption. This randomized, double-blind, placebo-controlled trial assessed the effects of tenapanor on serum phosphate concentration in patients… Expand

Paper Mentions

Blog Post
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
TLDR
Tenapanor significantly reduced elevated serum phosphate in patients with hyperphosphatemia receiving maintenance hemodialysis, and showed a significant benefit over placebo during the withdrawal period. Expand
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia
TLDR
Therapy with existing phosphate binders and add-on tenapanor resulted in a significant decrease in serum phosphorus level compared with the placebo group in patients with refractory hyperphosphatemia despite treatment with phosphate binder. Expand
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
TLDR
Following a marked increase in serum FGF23 in response to withdrawal of phosphate binders, tenapanor significantly decreased serum F GF23 in patients receiving hemodialysis with hyperphosphatemia. Expand
Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
TLDR
Administration of combination tenapanor plus phosphate binder treatment in patients receiving dialysis with hyperphosphatemia results in more pronounced reductions in intestinal phosphate absorption than if either agent is administered alone. Expand
Safety and Efficacy of Tenapanor for Long-term Serum Phosphorus Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)
Background: Treating hyperphosphatemia is a tenet of dialysis care. This trial assessed the safety and efficacy of tenapanor for the management of hyperphosphatemia. Methods: In this 52-week phase 3Expand
State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
TLDR
In this controversies perspective, the evidence base around binder use in CKD and kidney failure is discussed with a focus on comparisons of available binders. Expand
Strategies for Phosphate Control in Patients With CKD
TLDR
Currently available treatment approaches for controlling hyperphosphatemia are discussed, including dietary phosphate restriction, reduction of intestinal phosphate absorption, phosphate removal by dialysis, and management of renal osteodystrophy, with particular focus on practical challenges and limitations. Expand
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
TLDR
The latest preclinical and clinical data for two candidates in this novel drug class are reviewed: tenapanor, a small-molecule inhibitor of the sodium/hydrogen ion-exchanger isoform 3, and nicotinamide, an inhibitor of sodium–phosphate-2b cotransporters. Expand
The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
TLDR
The use of niacin over 3 years lowered serum phosphorous concentrations but did not affect other markers of mineral metabolism in participants with CKD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
TLDR
Reformulated lanthanum carbonate is an effective phosphate binder that may reduce daily tablet burden and patients and physicians reported significantly higher levels of satisfaction with reformulated Lanthanum Carbonate compared with previous phosphate binders, partly because of reduced tablet burden with higher dosage strengths. Expand
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
TLDR
Calcium acetate controls serum phosphorus and calcium-phosphate product more effectively than sevelamer hydrochloride and should remain the treatment of choice for hyperphosphatemia in hemodialysis patients, cost-benefit analysis indicates. Expand
Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial.
TLDR
Investigating the effect of limiting the intake of phosphorus-containing food additives on serum phosphorus levels among patients with end-stage renal disease resulted in modest improvements in hyperphosphatemia. Expand
Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
TLDR
Tenapanor treatment increased stool sodium and weight over placebo in patients undergoing hemodialysis, but over 4 weeks of treatment, there was no difference in interdialytic weight gain between patients treated with tenapanor and those receiving placebo. Expand
Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study
TLDR
Serum phosphorus levels were effectively maintained in patients converted from other phosphate-binder medications to lanthanum carbonate, with increased satisfaction and reduced tablet burden, and there were significant reductions in daily dose and daily tablet burden after conversion to lan Ethan carbonate. Expand
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
TLDR
PA21 was effective in lowering serum phosphorus in dialysis patients, with similar efficacy to sevelamer carbonate, a lower pill burden, and better adherence, and the PA21 maintenance dose was superior to the low dose in maintaining serum phosphorus control. Expand
Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients
TLDR
Age, Charlson comorbidity index, serum phosphate, and intact parathyroid hormone levels prior to HD initiation were strongly associated with serum phosphate levels after HD initiation and overall patient-reported phosphate binder usage increased. Expand
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
TLDR
The results of this crossover study show interesting trends with respect to onset and duration of action that warrant further investigation in longer-term studies. Expand
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
TLDR
Patients with CKD stages 3-5D using sevelamer have lower all-cause mortality compared with those using CBBs, and questions remain regarding phosphate binder benefits for patients with CKDs and not on dialysis. Expand
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
TLDR
RenaGel is a safe and effective alternative to oral calcium for the management of hyperphosphatemia in end-stage renal disease and is found to be as effective as calcium carbonate or acetate as a phosphate binder. Expand
...
1
2
3
4
5
...